Literature DB >> 25104748

Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy.

Jason T Bariteau1, Shay Tenenbaum2, Alexander Rabinovich3, James W Brodsky4.   

Abstract

BACKGROUND: Charcot neuroarthropathy in the developed countries is primarily associated with diabetic neuropathy. This study investigated a series of patients with Charcot arthropathy associated with idiopathic peripheral neuropathy to evaluate the natural history in these patients and to evaluate the efficacy of a treatment protocol used for diabetic Charcot joints.
METHODS: The records and radiographs of patients with Charcot arthropathy of the foot and ankle treated between 1986 and 2009 were retrospectively reviewed. Patients with known causes of or risk factors for peripheral neuropathy were excluded, identifying 82 feet in 59 patients with idiopathic neuropathy. Twenty-three (39%) were bilateral. The average age was 76 years and the average follow-up was 60 months. Data were analyzed for medical history and diagnoses, medications, anatomic classification of Charcot arthropathy, history of ulcerations, ambulatory status, shoe wear and bracing, and operative interventions. Patient care was based on previous published treatment algorithms, based on conservative management with operative intervention reserved for nonhealing ulcers, infection, and/or nonplantigrade, unbraceable feet. Therapeutic success was a plantigrade foot with healed soft tissue envelope that allowed weight-bearing.
RESULTS: In all, 55% involved the midfoot (type 1), 34% the hindfoot (type 2), and 11% the ankle, (type 3A). Seventy-one of 82 feet were successfully treated at the time of last follow-up. Thirty-six feet (43%) were treated nonoperatively with success in 33 (92%). Forty-six of 82 feet required operative intervention, with success at last follow-up in 38 (83%). There were 8 operative failures resulting in 2 transtibial amputations and 6 feet with persistent ulceration.
CONCLUSIONS: This series of patients with Charcot arthropathy associated with idiopathic neuropathy demonstrated a wider spectrum of Charcot arthropathy of the foot and ankle than has been previously recognized or documented. At the present time, heightened awareness is needed to promote accurate diagnosis and appropriate treatment in nondiabetic patients with Charcot arthropathy. LEVEL OF EVIDENCE: Level IV, retrospective case series.
© The Author(s) 2014.

Entities:  

Keywords:  Charcot arthropathy; idiopathic neuropathy

Mesh:

Year:  2014        PMID: 25104748     DOI: 10.1177/1071100714543649

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  5 in total

1.  Idiopathic Charcot Arthropathy of the Knee Presenting as a Bicondylar Tibial Plateau Fracture.

Authors:  Logan F Hanson; Cameron G Hanson; Kyle L Barner
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2018-07-17

2.  Midterm Fate of the Contralateral Foot in Charcot Arthropathy.

Authors:  Felix W A Waibel; Martin C Berli; Viviane Gratwohl; Kati Sairanen; Dominik Kaiser; Laura Shin; David G Armstrong; Madlaina Schöni
Journal:  Foot Ankle Int       Date:  2020-07-22       Impact factor: 2.827

3.  Clinical benefit and improvement of activity level after reconstruction surgery of Charcot feet using external fixation: 24-months results of 292 feet.

Authors:  Ulrich Illgner; Tymo Budny; Inna Frohne; Nani Osada; Jan Siewe; Hans H Wetz
Journal:  BMC Musculoskelet Disord       Date:  2014-11-22       Impact factor: 2.362

4.  Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot.

Authors:  Rasmus Bo Jansen; Tomas Møller Christensen; Jens Bülow; Lene Rørdam; Niklas Rye Jørgensen; Ole Lander Svendsen
Journal:  J Diabetes Res       Date:  2018-08-02       Impact factor: 4.011

5.  Long-term follow-up of conservative treatment of Charcot feet.

Authors:  Viviane Gratwohl; Thorsten Jentzsch; Madlaina Schöni; Dominik Kaiser; Martin C Berli; Thomas Böni; Felix W A Waibel
Journal:  Arch Orthop Trauma Surg       Date:  2021-04-07       Impact factor: 2.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.